-
Catridecacog, sold
under the
brand name
Tretten in the US and
NovoThirteen in the EU) is a
class of
recombinant factor XIII A-subunit
based biopharmaceutical...
- B02BD08
Coagulation factor VIIa B02BD10 von
Willebrand factor B02BD11
Catridecacog B02BD13
Coagulation factor X B02BD14
Susoctocog alfa B02BD15 Valoctocogene...
- Catapres-TTS
Catarase Cathflo Activase cathine (INN)
cathinone (INN)
Catiolanze catramilast (USAN, INN)
catridecacog (INN)
catumaxomab (INN)
Caverject Cayston...
- 1948. A 2005
conference recommended standardization of nomenclature.
Catridecacog Coagulation D-dimer
Factor XIII
deficiency Muszbek L,
Bereczky Z, Bagoly...
- extrinsic: VII/Eptacog alfa common: X II/Thrombin I/Fibrinogen XIII/
Catridecacog combinations:
Prothrombin complex concentrate (II, VII, IX, X, protein...
-
traditional treatment for
factor XIII deficiency. Novo Nordisk’s rFXIII,
catridecacog, was
approved by the US Food and Drug
Administration in 2014. Although...
